• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>ICO

ICO

  1. iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update

    iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update

  2. Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

    Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

  3. Research and Markets: Aspergillosis - Pipeline Review, H2 2014

    Research and Markets: Aspergillosis - Pipeline Review, H2 2014

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.